Background: The evidence from randomized trials on remdesivir for hospitalized patients with coronavirus disease 2019 (COVID-19) is conflicting. We conducted a systematic review …
WC Ko, JM Rolain, NY Lee, PL Chen, CT Huang… - International journal of …, 2020 - Elsevier
Since the end of 2019, an increasing number of cases of pneumonia were reported in Wuhan, followed by other cities and provinces in China and many other countries …
Introduction After emerging the global pandemic of SARS-CoV2 some preliminary studies demonstrated the efficacy of antiviral treatments. But shortly thereafter, inconsistencies in the …
B Young, TT Tan, YS Leo - The Lancet Infectious Diseases, 2021 - thelancet.com
Finding antivirals that reduce mortality from severe respiratory viral infections has proven challenging. Phase 3 trials of baloxavir and pimodivir for severe influenza were …
Background Interpretation of the evidence from randomised controlled trials (RCTs) of remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the …
AA Razzack, SA Hassan, SKR Pasya… - Infection & …, 2021 - ncbi.nlm.nih.gov
Background The World Health Organization guidelines did not make a recommendation on use of remdesivir based on disease severity. Little is known regarding effectiveness of …
L Pilgram, KS Appel, MM Ruethrich, CEM Koll… - Infection, 2023 - Springer
Objectives The use of remdesivir (RDV) as the first drug approved for coronavirus disease 2019 (COVID-19) remains controversial. Based on the Lean European Open Survey on …
Purpose This review was aimed to synthesise the best available evidence on the effectiveness and safety of remdesivir in the treatment of moderate to severe COVID-19 …
Clinical question What is the role of remdesivir in the treatment of severe covid-19? This guideline was triggered by the ACTT-1 trial published in the New England Journal of …